News Release|TSD Japan, Inc.

2010
March 12	Capital was increased.
2009
November 26	Change in Board of Directors
October 26	Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan.
September 14	Capital was decreased.
August 31	TSD-0014(HVJ-E) project was approved by the government-financed aid project for strategic sophistication of Basic Manufacturing Technology.
March 4	Our "Consulting for clinical development" appeared in the most prestigious business newspaper (NIKKEI) in Japan.
March 2	Start of Consulting for Clinical Development
February 2	Conclusion of Licence Agreement for HVJ Envelope
2008
December 16	Change in Board of Directors
October 28	Announcement of New Shares by Third Party Allocation
October 9	Conclusion of Basic Agreement for Future License Agreement for HVJ Envelope Vector
October 1	Corporate Profile(Capital stock, Directors, Number of Employees and Investors) and Corporate History were updated.
July 2	IND submitted for the therapeutic drug, COLAL-PRED^® for the treatment of ulcerative colitis.
June 1	Renewal of TSD Japan's logo and home page.
December 14	Osamu Shiho became Chairman, Yoshiharu Sakashita assumed the position of President & CEO.
2007
December 4	Obtained the rights to license and co-develop COLAL-PRED^® for the treatment of uncreative colitis in Japan from Alizyme Therapeutics Limited.
June 1	Tokyo Office was moved to the new location.
2006
November 24	Capital was increased.
September 1	Admitted as a member of the Osaka Pharmaceutical Manufactures Association.
August 18	Capital was increased.
May 31	Capital was increased.
March 29	Osaka Head Office was moved to the new location.